<DOC>
	<DOC>NCT01876719</DOC>
	<brief_summary>This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio. One-hundred twenty (120) patients are planned to be randomized. Each patient will receive AR08 (0.5, 1, or 2 mg per day) or matching placebo for seven (7) weeks.</brief_summary>
	<brief_title>AR08 for Treatment of ADHD in Children</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<criteria>1. Meets DSMIVTR criteria for a primary diagnosis of ADHD based on structured clinical interview, MINIKID, as assessed by the Investigator 2. Minimum score of 28 on the ADHDRSIV at Baseline 3. Male or female ages 6 17 years, inclusive, at the time of Screening 4. Weighs â‰¥21 kg (46 pounds). 5. Is functioning at age appropriate levels intellectually, as deemed by the Investigator. 1. Has a comorbid psychiatric diagnosis (comorbid psychiatric diagnosis will be established by the MINIKID interview). 2. Has a positive response to either question 4 or 5 of the Baseline /Screening version of the pediatric Columbia Suicide Severity Rating Scale (CSSRS) 3. History of daily usage (at least 28 days/month) of either antihypertensive or prophylactic antimigraine medications prior to Screening 4. Current usage of medications known to cause QTc prolongation or ADHD medications.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ADHD</keyword>
	<keyword>AR08</keyword>
	<keyword>adrenergic receptor agonists</keyword>
	<keyword>randomized, placebo-controlled clinical trial</keyword>
</DOC>